Edinburgh, Scotland-based mental health and neurology research company Caritas Neuro Solutions has signed a landmark partnership agreement with Mumbai, India-based digitally driven organisation Innvocept Solutions, enabling expansion of the company as a global player.
The move enables Caritas to run full service pharmaceutical and biotechnology clinical trials across the globe with staff based throughout India, Malaysia, Sri Lanka and Singapore in addition to existing capabilities throughout Europe.
Caritas, which launched in April 2017, is one of the world’s first commercial CROs (clinical research organisations) to specialise solely in neurological diseases.
The company’s profits are re-invested into running academic trials in mental health and mindset studies on behalf of charities and public sector organisations, such as currently working with NHS staff union Unison Lothian to study the effects of emotional wellbeing coaching within their workforce.
Innvocept was set up with a similar aim of providing small and medium-sized enterprises (SMEs) with cost effective solutions for drug development, to help promising new therapies can reach patients in a timely manner.
“I am delighted that we have managed to make this work as both companies share the same values of compassion, collaboration and integrity,” said Caritas chief executive Leigh Fell of the alliance. “Our skill sets complement each other and together we’ll be able to make a much more significant impact and really change lives.”
Life science has a strong history of success in Scotland and remains one of the country’s leading sectors, employing around 40,000 people. International collaborations such as this Asia-pacific deal provide significant contribution towards the Life Science Strategy for Scotland, which aims to grow the sector to £8 billion by 2025.
